posted on 2018-05-10, 00:00authored byAlf Claesson, Alexander Minidis
Reactive
metabolites are widely accepted as playing a pivotal role
in causing idiosyncratic adverse drug reactions (IDR). However, much
is unknown about the biological mechanisms of IDR, although the initiating
event in most cases is an attachment of a reactive intermediate to
macromolecules leading to immune-mediated responses. Reactive metabolites
are also involved in many mutagenesis/carcinogenesis events by reacting
with DNA. Drug designers thus have reasons to make large efforts to
avoid making test compounds having a liability to generate reactive
metabolites. In this Perspective we argue for using structural alerts
(SA) as the most straightforward way to link forecasting about chemical
hazards of planned test compounds to the accumulated knowledge base.
Although many SAs have been widely recognized and reviewed previously,
there are also a lot of observations that have no readily discernible
chemical interpretation. For drug designers to benefit from all published
data, the knowledge has to be organized in a way that is readily searchable
starting with a query structure. We propose that an increased number
of structural alerts with more details should be applied to obtain
improved decision support. The association of selected SAs with reference
drugs, whose proposed or hypothesized activation mechanisms build
the knowledge base, should be readily available in a format comprising
of small summaries with included hyperlinks for quick access to the
original literature, as outlined in the TOC illustration. Since some
structural alerts are present in drugs that do not cause idiosyncratic
adverse reactions or drug–drug interactions, it is important
to elaborate on the reasons for this discrepancy as much as possible.